SenesTech Inc(SNES) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 15 at 7:59 PM ET (Korea 10/16 08:59)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.36 | Insider Own | 4.26% | Shs Outstand | 5.3M | Perf Week | -7.32% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 20.22% | Insider Trans | - | Shs Float | 5.2M | Perf Month | -18.38% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.33 | Inst Own | 28.61% | Short Float | 0.53% | Perf Quarter | -52.81% |
| Income | -0.01B | P/S | 1.53 | EPS this Y | 28.97% | Inst Trans | -2.73% | Short Ratio | 0.32 | Perf Half Y | -58.64% |
| Sales | 0.00B | P/B | 0.59 | EPS next 5Y | 42.02% | ROA | -70.73% | Short Interest | 0.03M | Perf YTD | -68.69% |
| Book/sh | 1.14 | P/C | 0.72 | EPS past 3/5Y | 89.84% 80.37% | ROE | -107.41% | 52W High | -84.01% ($4.19) | Perf Year | -83.45% |
| Cash/sh | 0.94 | P/FCF | - | Sales past 3/5Y | 29.66% 51.1% | ROIC | -83.11% | 52W Low | 9.83% ($0.61) | Perf 3Y | -98.35% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 75.01% | Gross Margin | 61.5% | Volatility(W/M) | 16.97% 11.78% | Perf 5Y | -99.98% |
| Dividend TTM | - | EV/Sales | 0.48 | Sales Y/Y TTM | 13.43% | Oper. Margin | -303.66% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.81 | EPS Q/Q | 60.36% | Profit Margin | -294.73% | RSI (14) | 36.73 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.78 | Sales Q/Q | 23.2% | SMA20 | -7.18% ($0.72) | Beta | 0.23 | Target Price | $6.75 |
| Payout | - | Debt/Eq | 0.43 | Earnings | 2026/8/5 | SMA50 | -29.32% ($0.95) | Rel Volume | 683.9 | Prev Close | $0.64 |
| Employees | 24 | LT Debt/Eq | 0.39 | EPS/Sales Surpr. | 18.41% 28.01% | SMA200 | -56.93% ($1.56) | Avg Volume(3M) | 0.09M | Price | $0.67 |
| IPO | 2016/12/8 | Option/Short | No/Yes | Trades | 70255 | Volume | 58,417,046 | Change | 4.7% |
This small-cap bio/agriculture company develops and sells fertility-control products that manage rat and rodent populations through sterility (contraception) rather than rodenticides (poisons). Through ContraPest®, the first rat contraceptive registered with the U.S. EPA, and its premium soft-bait Evolve® product line, the company targets pest management professionals (PMPs), municipalities, and individual consumers, pursuing high-margin recurring revenue.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded more than usual. That is 68390% of its average volume.
SNES has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +29.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $153. Peers typically go for $146.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +73% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 28.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #60 of 62 in the industry
Based on market cap of $4M.
FAQ
What kind of company is SNES?
SNES belongs to the Basic Materials sector and operates in the Specialty Chemicals industry.
What is the market cap of SNES?
The market cap of SNES is approximately $4M, ranking 5,723 within its sector.
What is the 52-week high and low for SNES?
SNES has recorded a 52-week high of $4.19 and a low of $0.61.
